Orthofix Medical INC 8-K filings

Orthofix Medical Inc. announced its second quarter 2026 financial results, reporting a 4% increase in net sales and raising its full-year guidance for both net sales and adjusted EBITDA.

Orthofix Medical Inc. announced that CMS has reversed recent changes to Medicare reimbursement for non-invasive bone growth stimulators, returning rates to pre-May 18, 2026 levels.

Orthofix Medical Inc. shareholders approved an amendment to the stock purchase plan, increasing available shares, and re-elected the board of directors at the 2026 Annual Meeting.

Orthofix Medical Inc. revises its 2026 financial outlook downwards due to anticipated declines in Medicare reimbursement for non-invasive bone growth stimulators.

Orthofix Medical Inc. announced its first quarter 2026 financial results, showing steady execution and reaffirming its full-year financial guidance.

Orthofix Medical Inc. announced preliminary Q1 2026 net sales of $196.7 million, a 1.6% increase, and reaffirmed its full-year 2026 guidance, alongside a strategic realignment of its Spine leadership team.

Orthofix Medical Inc. announced robust fourth quarter and full-year 2025 financial results, driven by strong performance in Bone Growth Therapies and U.S. Limb Reconstruction, alongside an optimistic 2026 financial guidance and updated three-year targets.

Orthofix Medical Inc. reported strong third-quarter 2025 financial results, featuring accelerating net sales growth, significant adjusted EBITDA margin expansion, and positive free cash flow, while narrowing full-year sales guidance and raising the low end of adjusted EBITDA guidance.

Orthofix Medical Inc. reported robust second quarter 2025 financial results, showcasing significant adjusted EBITDA growth and positive free cash flow, while reaffirming full-year guidance.

Orthofix Medical Inc. announced the successful re-election of all ten directors, approval of executive compensation, and ratification of Ernst & Young LLP as its independent auditor at its 2025 annual meeting of shareholders.

Orthofix Medical Inc. reported its Q1 2025 financial results, updated its full-year net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance.

Orthofix Medical Inc. has entered into a new lease agreement for its Carlsbad, California office, effective April 1, 2025, with a term extending through October 31, 2037.

Orthofix Medical Inc. announced the appointment of Vickie Capps to its Board of Directors, effective March 11, 2025, increasing the board size to ten members.

Orthofix Medical Inc. reported record fourth-quarter net sales and provided full-year 2025 financial guidance, focusing on profitable growth opportunities.

Orthofix Medical Inc. has entered into a $275 million secured credit agreement with Oxford Finance LLC and other lenders, including a $160 million term loan and a $65 million delayed draw term loan facility.

Orthofix announced positive third-quarter results, highlighted by revenue growth across all segments, and introduced new three-year financial targets.

Orthofix Medical Inc. announced a 6% increase in net sales and raised its full-year 2024 financial guidance, driven by strong performance in Bone Growth Therapies and U.S. Spine Fixation.

Orthofix Medical Inc. announces shareholder approval for increased share reserves in its incentive and stock purchase plans, along with the appointment of new board and committee chairs, and the departure of a key executive.

Orthofix Medical Inc. announced a 7.7% increase in net sales and a significant improvement in adjusted EBITDA for the first quarter of 2024, leading to an upward revision of their full-year sales guidance.

Orthofix Medical Inc. has amended its cooperation agreement with Engine Capital, allowing the board flexibility in supporting certain director nominees based on fiduciary duties.

Orthofix Medical Inc. reports that three board members, including Stuart M. Essig, James F. Hinrichs, and Catherine M. Burzik, will not seek re-election at the upcoming 2024 annual meeting.

Orthofix Medical Inc. announced a 64% increase in fourth-quarter net sales and a 69% growth in full-year adjusted EBITDA, alongside issuing a positive outlook for 2024.

Orthofix Medical Inc. has appointed Julie Andrews as its new Chief Financial Officer, effective January 15, 2024.